Objective. We have previously established that the gene for neutrophil cytosolic factor 2 (NCF-2) predisposes to lupus, and we have identified lupus patients with point mutations that are predicted to cause reduced NADPH oxidase activity. We undertook this study to investigate the relationship between reduced leukocyte NADPH oxidase activity and immune dysregulation associated with systemic lupus erythematosus (SLE).
NCF-2-null and even NCF-2-haploinsufficient mice on the NZM 2328 background developed accelerated full-blown lupus with significantly accelerated lupus kidney disease. This was characterized by more rapid development of hyperactive B cell and T cell immune compartments, increased expression of type I interferonresponsive genes, and generation of neutrophil extracellular traps, which were observed even in the absence of NADPH oxidase activity.
Conclusion. Just as patients with chronic granulomatous disease who lack NADPH oxidase rarely develop SLE, NCF-2-null mice on a nonautoimmune background were susceptible to a chronic granulomatous disease-like opportunistic infection but did not develop lupus. In contrast, on a lupus-prone background, even haploinsufficiency of NCF-2 accelerated the development of full-blown lupus disease. This establishes an interaction between reduced oxidase activity and other lupus-predisposing genes, paralleling human SLE-associated variants predicted to have only reduced NADPH oxidase activity.
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disorder with extensive immune dysregulation and chronic inflammation affecting multiple organs. Its development is influenced by the effects of variants in multiple genes associated with immune regulation. Genome-wide association approaches followed by targeted association studies in SLE patients of various ethnicities and in relevant control subjects have established that NCF2, the gene for neutrophil cytosolic factor 2 (NCF-2), a critical NADPH oxidase (NOX) subunit, predisposes to lupus (1) (2) (3) (4) .
Leukocyte NADPH oxidase activates electron transfer from NADPH, generating O 2 -and derivative reactive oxygen species (ROS). The complex is composed of multiple subunits, 2 of which (cytochrome b a-chain [CYBA] and cytochrome b b-chain [CYBB], the latter of which is also known as NOX-2) are localized in cellular membranes. Upon activation, the 3 cytosolic subunits (NCF-1, NCF-2, and NCF-4) translocate to the membrane, where they, along with GTP-bound Rac (Rac-GTP) (Rac1 or Rac2), form the active NOX-2 enzyme (5, 6) . In resting cells, Rac-GDP is present as a complex with Rho-GDP dissociation inhibitor, but this complex rapidly dissociates and Rac-GTP forms in stimulated cells (6) . This process is facilitated by activation of guanine nucleotide exchange factors (GEFs) and is accompanied by translocation of Rac to the membrane (5, 6) . The Vav proteins (Vav-1, Vav-2, and Vav-3) are a family of GEFs for Rho family GTPases; Vav-1 and Vav-3 expressed in leukocytes regulate Rac. Upon phosphorylation, Vav has GEF activity for Rac, facilitating the transition of Rac to an active GTP-bound state (7) . Superoxide-generating leukocyte NADPH oxidase has long been considered to be of main importance for the generation of ROS inside the phagosome, where these ROS promote the killing of microbes, or for the release of extracellular ROS, which are mainly thought to contribute to tissue damage. However, there is increasing recognition that NADPH oxidase-derived ROS also have immunomodulatory effects.
NADPH oxidase activity is absent or profoundly decreased in patients with chronic granulomatous disease, an inherited immune deficiency due to recessive mutations in CYBB, CYBA, NCF1, NCF2, or NCF4 that results in bacterial and fungal infections and aberrant inflammation (8, 9 ). An inflammatory bowel disease-like syndrome occurs in ;20% of patients with chronic granulomatous disease (10) , and lesions resembling discoid lupus occur in ;10% of these patients (11) . However, full-blown autoimmune disease, including SLE, is uncommon (12) (13) (14) .
Our prior work identified SLE patients who harbor 1 of 2 variant alleles encoding NCF-2. Both variant alleles have point mutations in the NCF-2 PB1 domain that interacts with NCF-4, another critical oxidase subunit, and with the Vav GEF, an important regulator of NADPH oxidase. One of the mutations causes a histidine-to-glutamine substitution at amino acid 389 (H389Q) in North American lupus subjects of European (2) or Hispanic descent (4), while the other results in an arginine-to-tryptophan substitution at amino acid 395 (R395W) in North American lupus subjects of Hispanic descent but not those of European ancestry (4) . Likely mechanisms for the functional consequences of these variants were obtained using protein-protein docking and chemical surface complementarity analyses. The H389Q mutation was predicted to reduce NCF-2 binding efficiency to Vav. Indeed, our site-specific mutations and model cell expression studies showed that the H389Q mutation caused a 2-fold decrease in ROS production downstream of Vav-dependent Fcg receptor signaling, but had no effect on Vav-independent NADPH oxidase activity elicited by phorbol myristate acetate (PMA) (2) . Similar computational modeling studies showed that NCF-2 395R is located at the critical junction of NCF-2, NCF-4, Vav, and Rac. The R395W substitution in NCF-2 is predicted to destabilize these interactions and to cause reduced oxidase activity (4) .
Because of the substantial variability in human SLE (including clinical, genetic, and disease activity factors and medication regimens encountered in human disease), mechanistic studies using human leukocyte samples to understand the role of NCF-2 mutations in SLE would be highly challenging to interpret. On the other hand, the components of NADPH oxidase are all extremely well conserved between mice and humans (4) . To study the effects of absent or reduced (haploinsufficient) NCF-2 expression in a more uniform setting, we produced NCF-2-null mice on the nonautoimmune C57BL/6 (B6) background and backcrossed the mutation onto NZM 2328 mice, a model of spontaneous lupus (15) . We present the results of our investigation of the relationship between reduced leukocyte NADPH oxidase activity and immune dysregulation associated with SLE. Our findings link the genetic association between NCF-2 variants and lupus to experimental evidence showing that even haploinsufficient NCF-2 expression (and consequent reduction in NADPH oxidase activity) accelerates the development of lupus when other genetic risk factors are present, as in NZM 2328 mice. The NCF-2 2/2 mice on the B6 background were backcrossed onto the SLE-prone NZM 2328 mice (hereinafter called NZM mice). Introgression of the genotypes was accelerated by a marker-assisted selection protocol using microsatellite markers spanning the entire genome and including markers to ensure that all known SLE susceptibility loci remained intact (16, 17) . Results are presented for mice from the N6 backcross generation or later, at which time all mice bore the NZM genotype at all tested markers. NCF-2 2/2 B6 mice housed in the same facility were used for control studies in the B6 background.
MATERIALS AND METHODS
Aspergillus fumigatus pneumonia induction. A fumigatus (clinical isolate 90240; ATCC) was grown, and conidia were harvested as previously described (18) , with minor modifications. A fumigatus was cultured on Sabouraud dextrose agar for 3 days at 378C. Conidia were harvested by pipetting 5-10 ml of phosphate buffered saline (PBS) onto each plate, gently scraping with a cell scraper, and filtering through Miracloth (Sigma-Aldrich) and a 40 mm strainer. Via nasopharyngeal instillation, mice received 1 million conidia suspended in 25 ml PBS containing 5% colloidal carbon. Mice were killed after 48 hours, and lungs were lavaged with 1 ml of PBS containing 2 mM EDTA and 2% fetal bovine serum (FBS). Lavage fluid was spun down, and after red blood cell lysis with ACK lysis buffer, cell counts were quantified on a hemocytometer, and cytospin slides were prepared for WrightGiemsa staining and analyzed by light microscopy. Lungs were inflated with neutral buffered formalin, fixed overnight, and embedded in paraffin. Sections were stained with hematoxylin and eosin (H&E) for assessment of pathologic changes and with Gomori's methenamine-silver for assessment of hyphae.
NADPH oxidase activity. NADPH oxidase activity in bone marrow-derived macrophages (BMMs) and bone marrow-derived dendritic cells (BMDCs) was assessed using a 1-hour-long kinetic chemiluminescence assay with 300 mM lucigenin in a SpectraMax L luminometer (Molecular Devices) and analyzed by SoftMax Pro Software (Molecular Devices). After overnight culture, cells were washed with PBS 3 times before lucigenin was added. To measure ROS, BMMs or BMDCs were either left untreated or treated with 160 mg/ml serum-opsonized zymosan, as described elsewhere (19) . Total ROS and intracellular ROS following treatment with serumopsonized zymosan were measured as relative luminescence units (RLUs) and presented as the percentage of response in wild-type (WT) mice following stimulation with serumopsonized zymosan. Superoxide production by neutrophils was assessed either by the kinetic reduction of cytochrome c at 378C for 1 hour using a SpectraMax 340PC microplate reader (Molecular Devices) (20) or by a kinetic chemiluminescence assay with 125 mM luminol in a SpectraMax L luminometer (21) . Neutrophils were either left untreated or treated with 200 or 250 ng/ml PMA, and data were analyzed by SoftMax Pro Software. Data are presented as Vmax (nmoles O 2 -/ minute/10 7 cells) or RLUs. Renal histology score. Sections of formalin-fixed kidneys were stained with H&E, Masson's trichrome, and periodic acid-Schiff and were assessed by light microscopy for glomerular activity (hypercellularity, necrotizing lesions, karyorrhexis, cellular crescents, hyaline deposits), tubulointerstitial activity (interstitial cellular infiltration, tubular cell necrosis), chronic glomerular pathology (glomerulosclerosis, fibrous crescents), and chronic tubulointerstitial pathology (tubular atrophy, interstitial fibrosis). Each category was subjectively scored on a 0-3 scale, for a maximum composite score of 12.
Quantitative real-time PCR for type I interferon (IFN)-responsive gene transcription. Total RNA from spleen was prepared using an RNeasy Plus Mini kit (Qiagen) and was reverse transcribed to complementary DNA using random hexamers with a SuperScript III Reverse Transcriptase kit in accordance with the instructions of the manufacturer (Invitrogen). TaqMan gene expression primers were used for the indicated genes, and reverse transcriptase (RT)-PCR was performed on a 7900HT Fast Real-Time PCR System (Applied Biosystems) using TaqMan Universal PCR Master Mix (Thermo Fisher Scientific). GAPDH primers were used to normalize gene expression. Using the 2 -DDCt method, target C t -GAPDH C t was analyzed and multiplied with an arbitrary number (10 6 ) for graphs showing relative expression.
Analysis of neutrophil extracellular traps (NETs). NETosis assays were performed generally as described previously (22, 23) . Purified neutrophils were resuspended in RPMI 1640 without serum and transferred to poly-L-lysine-coated wells in 8-well Lab-Tek II glass chamber slides (Thermo Fisher) at 2 3 10 6 /ml (2 3 10 5 cells per well). Fifty microliters of each stimulus (serum obtained from 8-9-month-old female NZM mice, diluted to 1% in RPMI 1640, PMA 100 nM concentration or media alone) was added, and slides were incubated at 378C in 5% CO 2 for 7 hours. Cells were then fixed with 4% paraformaldehyde for 20 minutes and washed with PBS. After blocking with 2% bovine serum albumin and 2% goat serum in PBS-0.05% Tween for 1 hour, cells were stained with primary antineutrophil elastase (rabbit polyclonal, 1:80 dilution; Abcam) or anti-histone H3 (citrulline 2, 8, 17) (rabbit polyclonal, 1:200 dilution; Abcam) followed by Alexa Fluor 488-labeled goat anti-rabbit antibody (1:400 dilution; Invitrogen) and ProLong Gold Antifade with DAPI (Life Technologies), and coverslips were then affixed. Photographs were taken at 4003 magnification with a Zeiss AxioCam HRc attached to an Olympus BX60 microscope, and images were scored in a blinded manner to enumerate cells and cells undergoing NETosis. Criteria for scoring a neutrophil as undergoing NETosis were based on the release of extracellular DNA that colocalized with citrullinated histone or neutrophil elastase; at least 200 neutrophils were scored for each subject.
Anti-NET and anti-cathelicidin-related antimicrobial peptide (anti-CRAMP) enzyme-linked immunosorbent assays. Assays were adapted from Knight et al (22) . High-binding 96-well Costar assay plates (Corning) were coated with 100 ng/ml of NET proteins or 5 mg/ml of mouse CRAMP (AS-61305; AnaSpec) in PBS and incubated overnight at 48C. NET protein was prepared by incubating NZM mouse bone marrow neutrophils with 2.5 mM PMA for 6 hours, collecting supernatants, and digesting with micrococcal nuclease and DNase. Plates were then blocked with 10% FBS in PBS for 1 hour at room temperature, followed by overnight incubation at 48C with experimental mouse serum diluted 1:100 in blocking buffer. Plates were then incubated with anti-mouse IgG (Sigma) followed by horseradish peroxidase-conjugated streptavidin (SouthernBiotech), each diluted 1:2,000 in blocking buffer for 1 hour at room temperature. Finally, tetramethylbenzidine substrate (Sigma) was added, and absorbance was measured at 450 nm after addition of a stop reagent (Sigma). Statistical analysis. All analyses were performed using SigmaStat software (SPSS). Parametric testing between 2 groups was performed by unpaired t-test and among $3 groups by oneway analysis of variance (ANOVA). When data were not normally distributed or the equal variance test was not satisfied, nonparametric testing was performed by Mann-Whitney rank sum test between 2 groups and by Kruskal-Wallis one-way ANOVA on ranks among $3 groups. Proteinuria and survival curves were constructed according to the Kaplan-Meier nonparametric method.
RESULTS
Establishment of NCF-2-null and haploinsufficient mice. We generated mice with a null allele for Ncf2 using C57/B6N ES cells with a mutant Ncf2 allele harboring a conditional-ready insertion and loxP sites that can delete exon 3 to generate a frameshifted transcript and null allele ( Figure 1A ). These mice were bred to a generalized deleter strain to globally excise Ncf2 exon 3. We established a colony of NCF-2 2/2 and NCF-2 1/2 B6 mice with the Cre transgene bred out. Absence of NCF-2 protein and NADPH oxidase activity in NCF-2 2/2 B6 mice was verified by immunoblotting and enzyme assays (see Supplementary Figure 1 , http://onlinelibrary.wiley. com/doi/10.1002/art.40141/abstract).
Development of A fumigatus pneumonia in NCF-2-null mice but not NCF-2-haploinsufficient mice. NADPH oxidase is essential to preventing progressive pneumonia with the opportunistic mold A fumigatus following inhalation of spores (conidia), which is a life-threatening infection in patients with chronic granulomatous disease. However, heterozygous carriers are not at any risk. NCF-2
, and NCF-2 2/2 B6 mice were challenged with 1 3 10 6 conidia (4 mice of each genotype), and the lungs were analyzed 48 hours later. NCF-2 1/1 and NCF-2 1/2 B6 mice showed little if any inflammatory cell infiltrate and no germinated hyphae on histologic examination of either lung tissue or bronchoalveolar lavage (BAL) fluid ( Figure 1B ; also see Supplementary Figure 2 , http://onlinelibrary.wiley.com/ doi/10.1002/art.40141/abstract). However, lungs from all 4 NCF-2 2/2 mice showed multiple foci of inflammatory cells that contained germinated hyphae ( Figure 1B) , and numerous neutrophils, many associated with hyphae, were present in BAL fluid (see Supplementary Figure 2) . The incidence of pneumonia in NCF-2 2/2 mice (4 of 4 mice) was significantly greater than that in NCF-2 1/1 and NCF-2 1/2 mice (0 of 4 mice in each group) (P , 0.005). Thus, NCF-2 2/2 mice were susceptible to A fumigatus pneumonia, while both WT and NCF-2 1/2 heterozygous mice were resistant.
Accelerated lupus nephritis in NCF-2-null and NCF-2-haploinsufficient female NZM mice. We bred NCF-2 2/2 B6 mice to NZM mice to analyze the effect of complete or partial Ncf2 deletion on full-blown SLE. Using the NZM strain eliminates the need to backcross a transgene separately to the NZB and NZW parental background. We used a marker-assisted selection protocol, which accelerates the introgression of genes by using genetic markers to facilitate this process (16, 24) . Furthermore, the use of locus-specific markers ensures that the identified SLE susceptibility loci in NZM mice remain intact during backcrossing. This is especially relevant in our case because both the Sle1 locus and the Ncf2 gene are on chromosome 1. Ncf2 is at 65.05 cM, while Sle1 is at 76.73 cM. Their 11-cM separation means that we expected a recombination event 11% of the time (i.e., for 100 mice screened, 11 mice would have both sites). This methodology ensured the generation of NCF-2 2/2 NZM mice with the lupus susceptibility locus Sle1 intact.
As shown in Figure 1C , NCF-2 protein was not detected in BMMs and BMDCs from NCF-2-null NZM mice, while NCF-2 1/2 NZM mice showed reduced expression of NCF-2. Similar results were obtained for neutrophils (not shown). NADPH oxidase activity in macrophages, DCs, and neutrophils was absent in the NCF-2-null NZM mice, while heterozygous (haploinsufficient) mice showed partially reduced, but statistically significant, levels of ROS in all 3 cell subsets compared to WT mice ( Figures 1D  and E) .
Large groups of female NCF-2 2/2 and NCF-2
mice on the NZM background were studied for 12 months and compared to female WT NZM mice and NCF-2-null B6 mice. Clinical disease, serology, and immunopathology were evaluated in each group. NCF-2 2/2 NZM mice had accelerated full-blown disease, while NCF-2 2/2 mice on the non-lupus B6 background did not develop lupuslike disease. As shown in Figure 2A , female NCF-2 2/2 mice displayed accelerated kidney disease, as determined by both proteinuria and mortality. Furthermore, even NCF-2 1/2 lupus mice with haploinsufficiency and reduced, 
ACCELERATED LUPUS IN NCF-2-DEFICIENT MICE
but definitely not absent, NADPH oxidase activity (Figures 1D and E) had significantly accelerated lupus kidney disease. This is a crucial finding, as it shows that even a partial reduction in NADPH oxidase activity can accelerate the development of lupus. Both NCF-2 2/2 and NCF-2 1/2 NZM mice were significantly different from the corresponding WT NZM mice in both proteinuria and mortality (both P , 0.001 by log rank test [KaplanMeier method]). The fact that development of severe proteinuria ($300 mg/dl) closely correlated with mortality in each mouse cohort supports the notion that these mice died as a consequence of kidney disease.
Development of renal immunopathology was consonant with their clinical course. Renal pathology, including glomerular hypercellularity, glomerular crescents, mesangial matrix deposition, and interstitial inflammation, was seen in 4-month-old female NCF-2 2/2 mice ( Figure 2B ) as well as glomerular deposition of IgG and C3. Quantitatively, 4-month-old female NCF-2 2/2 and NCF-2 1/2 mice showed significantly greater renal histology scores than did age-matched female WT NZM mice ( Figure 2C ). In fact, the renal histology score in female NCF-2 2/2 mice at age 4 months was not significantly different from that of female WT NZM mice at age 7.5 months ( Figure 2C ). Using flow cytometry, a hyperactive B cell immune compartment in NCF-2-mutated lupus mice was evident by age 3.5-5 months. Thus, as shown in Figures 3A-G, compared to 5-7-month-old WT NZM mice, there was an increase in total B cells and increased numbers of germinal center (GC) B cells, follicular B cells, CD691 activated B cells, and antibodyproducing plasma cells as well as enhanced CD80 and CD86 expression. Furthermore, the NCF-2-mutated lupus mice showed increased autoantibody levels. Among the different autoantibodies found in lupus, IgG anti-double-stranded DNA (anti-dsDNA) antibodies are the most closely correlated with clinical outcome in mice and humans with SLE (25) . Figure 3H compares levels of IgG anti-dsDNA antibodies between the different cohorts of female mice. NCF-2 2/2 and NCF-2 1/2 lupus mice both showed increased anti-dsDNA levels compared to 3-5-month-old WT NZM mice. Finally, both the NCF-2 2/2 and NCF-2 1/2 NZM mice showed spontaneous GC formation (see Supplementary Figure  3A abstract). Although nonautoimmune B6 mice did not show spontaneous GC formation, this was observed in a small proportion (3 of 11) of NCF-2 2/2 B6 mice (see Supplementary Figure 3B ). These were the mice that also showed evidence of anti-dsDNA autoantibody production ( Figure 3H) . A hyperactive T lymphocyte compartment was also demonstrated in NCF-2-mutated mice on the NZM background (Figure 4) , including elevated total CD31 T cells ( Figure 4A ) and increased numbers of both CD41 and CD81 T cells (Figures 4B and C) . Notably, a substantial fraction of CD41 T cells displayed the phenotype Figure 4F ) and/or recently activated T cells (CD41 CD691) ( Figure 4G ). There was a gradual shift toward this T cell phenotype in lupus-prone NZM female mice, with peak levels coinciding with full-blown lupus nephritis at age 7.5-10 months ( Figure 4F) . Notably, Treg cells were increased in the NCF-2 1/2 mice, but CD41 Th17 cells were not significantly affected in the mutant mice ( Figures 4D and E) .
Up-regulated transcription of type I IFNresponsive genes in NCF-2-deficient mice. Given that patients and mice with chronic granulomatous disease show a type I IFN signature (26), we analyzed the expression of these genes in NCF-2-null lupus mice using quantitative RT-PCR. At age 8 weeks, the composition of immune cells in the B cell, T cell, and myeloid compartments was similar in NCF-2 2/2 NZM mice and WT NZM mice (see Supplementary Figure  4 , http://onlinelibrary.wiley.com/doi/10.1002/art.40141/ abstract). However, as shown in Figure 5A , we identified a type I IFN signature in splenocytes from NCF-2-deficient NZM lupus mice that was already evident by age 7-8 weeks, as demonstrated by the significantly increased expression of IFN-responsive genes compared to that in age-matched WT NZM mice. In contrast, expression of type I IFN genes in splenocytes from 7-8-week-old NCF-2 2/2 B6 mice was similar to that in splenocytes from WT B6 mice ( Figure 5B ).
NETosis in NCF-2-null NZM mice. A form of neutrophil cell death called NETosis in which DNA coated with various proteins is released into the extracellular environment forming a NET (27, 28) appears to be integral to SLE pathology. While NADPH oxidasederived ROS are required for NETosis induced by PMA, recent studies show that NADPH oxidase was not required to induce NETs elicited by soluble IgG immune complexes (ICs) (29) or RNP ICs (30, 31) . We evaluated the ability of NCF-2-deficient NZM mice to 2/2 NZM mice were age 3.5-5 months, while NCF-2 1/2 NZM mice were age 5-6 months. WT NZM, WT B6, and NCF-2 2/2 B6 mice were age 5-7 months. See Figure 2 for other definitions.
generate extracellular traps. Neutrophils isolated from the marrow of WT NZM and NCF-2 2/2 NZM mice at age 4-5 months exhibited spontaneous NETosis ( Figure  6A ). In contrast, there was minimal or no spontaneous NETosis in WT and NCF-2 2/2 B6 mice ( Figure 6B ). We quantitated the percentage of neutrophils undergoing spontaneous NETosis ( Figure 6D ), which was significantly higher in WT NZM and NCF-2 2/2 NZM mice than in corresponding age-and sex-matched nonautoimmune WT B6 and NCF-2 2/2 B6 control mice. There was no significant difference in NETosis between WT NZM and NCF-2 2/2 NZM mice. As expected, neutrophils from NCF-2 2/2 NZM mice did not exhibit NETosis in response to PMA (see Supplementary Figure 5 , http://onlinelibrary.wiley.com/ doi/10.1002/art.40141/abstract). However, neutrophils from NCF-2 2/2 NZM mice were capable of undergoing lupus serum-induced NETosis in vitro, as did neutrophils from WT NZM mice ( Figure 6C ; also see Supplementary Figure 5 ). Furthermore, NCF-2 2/2 NZM mice appeared capable of generating NETs in vivo. Anti-NET antibody levels in NCF-2-deficient lupus mice were similar to those seen in NCF-2-sufficient (WT) NZM mice ( Figure 6E) . CRAMP is the mouse homolog of the human neutrophil granule protein LL37, an important component of NETs and NET-associated plasmacytoid dendritic cell (PDC) activation in human lupus (32) . As shown in Figure 6F , NCF-2 2/2 NZM mice also had NETosis-associated anti-CRAMP autoantibodies in their serum, further supporting the in vivo occurrence of NETosis in these mice. While levels of anti-NET and anti-CRAMP autoantibodies were not significantly different between NCF-2 2/2 NZM and WT NZM mice, they were significantly increased in comparison to their levels in B6 control mice ( Figures  6E and F) .
DISCUSSION
Forward genetic approaches, in which human populations were investigated in order to identify the genes involved in SLE, have clearly established NCF-2 variants as part of the genetic predisposition to disease development (2) (3) (4) . Further mechanistic analyses of the 2/2 and WT NZM mice and in NCF-2 2/2 and WT B6 mice, quantitated by microscopy as described in Materials and Methods. E and F, Autoantibodies to NETs (E) or cathelicidin-related antimicrobial peptide (CRAMP) (F) in serum, tested as described in Materials and Methods. Sera from 4-5-month-old female NCF-2 2/2 NZM mice, WT NZM mice, and WT B6 mice were compared. The OD index compares each absorbance value to the mean value in B6 controls. Each symbol represents an individual mouse. Data are shown as box plots. Each box represents the 25th to 75th percentiles. Lines inside the boxes represent the median. Lines outside the boxes represent the 10th and 90th percentiles. NS 5 not significant (see Figure 2 for other definitions).
role of NCF-2 in human subjects with SLE have inherent shortcomings due to involvement of multiple genes, in which each gene contributes modestly to the disease phenotype, often in interaction with other genes and/or environmental factors, rendering infeasible experimentation to isolate the effect of reduced expression of NCF-2. In the present study, we used a reverse genetic approach, in which we characterized the effect of the NCF-2 gene by perturbing it in the NZM mouse model of spontaneous lupus and then elucidated its effects on the phenotype of SLE. Our results show that not only NCF-2-null mice, but also NCF-2 1/2 haploinsufficient lupus mice with only partial reduction in NADPH oxidase activity, have significantly accelerated development of full-blown lupus disease. This is demonstrated on the clinical, pathologic, serologic, and immune cellular levels.
As in chronic granulomatous disease in humans, NCF-2 2/2 mice on the nonautoimmune B6 background developed severe A fumigatus pneumonia when challenged with the opportunistic mold A fumigatus, similar to gene-targeted mice with chronic granulomatous disease lacking either the CYBB or NCF-1 NADPH oxidase subunits (18, 33, 34) . However, WT and NCF-2 1/2 heterozygous mice were both resistant, also as in humans. Importantly, NCF-2 2/2 mice did not develop lupus-like disease, although skin and soft tissue infections resembling those described in other colonies of mice with chronic granulomatous disease (35) occurred in ;5% of these mice. A similar small minority of NCF-2 2/2 mice on the NZM background also developed such infections. Such lupus mice have been excluded from the experiments reported here. On the other hand, NCF-2-haploinsufficient mice did not develop a chronic granulomatous disease-like infection at all. It is also noteworthy that only a small minority of NCF-2
2/2 B6 mice tested positive for spontaneous GC formation and autoantibodies, including anti-dsDNA, but none of the NCF-2 2/2 B6 mice in our colonies developed full-blown lupus-like autoimmune disease.
Our findings in mice resemble the situation in humans: although elevated autoantibodies and some other signs of autoimmunity are described in subjects with chronic granulomatous disease who have significantly diminished NADPH oxidase activity, full-blown SLE is very rare. On the other hand, in the context of a lupus genetic background, NCF-2-haploinsufficient NZM mice with reduced, but definitely not absent, NADPH oxidase activity have significantly accelerated lupus disease. This is a crucial finding, as it shows that even a partial reduction in NADPH oxidase activity can accelerate the development of lupus, a situation paralleling that in humans with SLE who have variants predicted to confer only reduced NADPH oxidase activity.
An emerging theme in the pathogenesis of SLE is the interplay among neutrophils, their release of NETs, activation of PDCs to produce type I IFNs, and lupus-associated endothelial and organ damage (36) . ICs as well as interleukin-17 and other cytokines are among the agents that can induce NETosis, which can be enhanced by IFNs (32, 37) . NET fragments delivered to PDCs in vitro have a proinflammatory effect, resulting in the production of type I IFN (32, 38) , which may be relevant to the IFN gene signature observed in ;50% of patients with SLE (39) . NET material may also be a source of autoantigens (32, 36, 40) . NZM mice replicate most features of human lupus associated with NET formation, including the tendency toward enhanced baseline NETosis, the ability of lupus serum to induce NET formation in normal mouse neutrophils, the ability of NET-derived material to serve as a source of autoantigens, and deposition of NET-like material in diseased kidney (22) .
The current study demonstrated that neutrophils from NCF-2-deficient NZM mice were able to generate NETs similar to those generated by neutrophils from NCF-2-sufficient (WT) NZM mice upon stimulation in vitro with lupus serum from NZM mice. Moreover, NCF-2 2/2 NZM mice exhibited anti-NET and anti-CRAMP autoantibodies, which supports the conclusion that NETs can be generated in vivo even in the absence of NADPH oxidase activity in lupus-prone mice. In contrast, Campbell and colleagues (41) reported that Xlinked CYBB (NOX-2)-null MRL-Fas lpr mice have exacerbated lupus disease despite lacking the ability to generate NETs, and they therefore proposed that NETosis does not contribute to SLE pathogenesis and its absence may even exacerbate SLE. However, only PMA-induced NETosis in vitro was analyzed in that study, and recent studies showed that NETs elicited by soluble IgG ICs (29) or RNP ICs (30,31) do not have a requirement for NADPH oxidase-generated ROS. While the role played by NETosis in the onset and progression of lupus remains to be fully understood, an important conclusion from our work presented herein is that lupus-associated NETosis does not require NADPH oxidase activity.
Of note, NCF-2-deficient NZM mice exhibited increased expression of type I IFN-responsive genes compared to NCF-2 1/1 NZM mice, which preceded the development of full-blown disease; this is noteworthy given the well-known association of an activated type I IFN axis with SLE (39) . This observation suggests that one potential mechanism by which NADPH oxidase deficiency acts as a risk factor in a lupus-prone genetic background is through increased expression of type I IFN-regulated genes. Additional work needs to be done to determine the drivers of type I IFN-regulated gene expression in NADPH oxidase deficiency, which also occurs in the absence of autoimmune disease in NADPH oxidase-deficient humans and mice, including those raised under gnotobiotic conditions (26) .
Additional mechanisms by which diminished NADPH oxidase activity might promote inflammation and autoimmunity include impaired digestion of microbes or debris, followed by increased Toll-like receptor stimulation and/or altered redox status of cellular proteins resulting in increased proinflammatory cytokine production via up-regulated MAP kinase, NF-kB, and other pathways (42) (43) (44) . Collectively, our results are consistent with the mechanistic notion that reduced NADPH oxidase activity amplifies multiple proinflammatory signaling pathways that synergize with other lupuspredisposing genes in inducing pathogenesis. Thus, NCF-2 2/2 and NCF-2 1/2 lupus mice both show evidence of accelerated onset of lupus nephritis with marked renal deposition of inflammatory cells, increased anti-dsDNA levels, and characteristic hyperactivity in both B and T cell compartments with both compartments expressing increased activation markers in flow cytometry analyses of spleen cells. Moreover, neutrophils from NCF-2 2/2 NZM mice were capable of NETosis, and antibodies consistent with the occurrence of NETosis in vivo were detected.
Interestingly, the NCF-2 variants we have described (2, 4) increase the risk of developing SLE, but so far, we have not detected any striking differences in the clinical spectrum of disease between SLE patients with these NCF-2 variants and SLE patients without them. Similarly, while the disease phenotype appears earlier and is accelerated in our NCF-2-deficient lupus mice, the clinical, serologic, and pathologic phenotype is no different qualitatively from that seen in the slower disease development in the original NZM mouse model. The fact that we have not as yet identified any unique phenotype in NCF-2-deficient NZM mice that is not seen in NCF-2-sufficient NZM mice parallels the lack of a unique clinical phenotype in subjects with SLE who have NCF-2 mutations. It is therefore likely that the proinflammatory immunologic effects of reduced NADPH oxidase activity in our mice, as in humans with NCF-2 variants, occur in the original process of disease establishment.
Taken together, our reverse genetic results are consistent with and enhance our forward genetic work in human SLE. Our findings suggest that NADPH oxidase-derived ROS, in addition to their microbicidal effects, may act as essential regulatory molecules with the capacity to affect a variety of cellular processes of importance for immune regulation and limiting inflammation. While impaired host defense results from absent NADPH oxidase activity, even haploinsufficiency accelerated the development of lupus when combined with other lupus-predisposing genes. This study identifies a new experimental system that will aid in dissecting underlying mechanisms by which a deficiency of NADPH oxidase-derived ROS affects the development of lupus. This work also advances our understanding of lupus pathogenesis and may inform future therapeutic approaches for the subgroup of patients with NADPH oxidase gene variants.
